share_log

Zymeworks Inc. (NASDAQ:ZYME) Analysts Just Slashed Next Year's Revenue Estimates By 16%

Zymeworks Inc. (NASDAQ:ZYME) Analysts Just Slashed Next Year's Revenue Estimates By 16%

Zymeworks Inc.(納斯達克:ZYME)分析師剛剛下調了明年的營業收入預估16%
Simply Wall St ·  11/08 19:55

The analysts covering Zymeworks Inc. (NASDAQ:ZYME) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic. Bidders are definitely seeing a different story, with the stock price of US$16.77 reflecting a 22% rise in the past week. It will be interesting to see if the downgrade has an impact on buying demand for the company's shares.

覆蓋Zymeworks Inc. (納斯達克:ZYME) 的分析師今天向股東們傳遞了一劑負面消息,對明年的法定預測進行了重大修訂。他們對營業收入的預估有相當嚴格的下調,或許是對之前預測過於樂觀的一種隱含承認。競標人顯然看到了不同的情況,美元16.77的股價反映了過去一週上漲了22%。看看這次下調是否對公司股票的購買需求產生影響,將會非常有趣。

After the downgrade, the seven analysts covering Zymeworks are now predicting revenues of US$101m in 2025. If met, this would reflect a substantial 62% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$120m in 2025. The consensus view seems to have become more pessimistic on Zymeworks, noting the measurable cut to revenue estimates in this update.

在下調之後,對Zymeworks進行覆蓋的七位分析師現在預測2025年的營業收入爲10,100萬美元。如果達到這一水平,將反映出銷售額較過去12個月實現了大幅增長的62%。在最新的預估之前,分析師們預測2025年的營業收入爲12,000萬美元。共識觀點似乎對Zymeworks變得更爲悲觀,特別注意了這次更新中對營業收入預估的顯著下調。

big
NasdaqGS:ZYME Earnings and Revenue Growth November 8th 2024
NasdaqGS:ZYME 2024年11月8日的盈利和營收增長

The consensus price target rose 9.0% to US$15.15, with the analysts clearly more optimistic about Zymeworks' prospects following this update.

共識目標價上漲了9.0%,達到15.15美元,分析師們顯然對Zymeworks的前景更爲樂觀。

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Zymeworks' rate of growth is expected to accelerate meaningfully, with the forecast 47% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 38% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 21% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Zymeworks to grow faster than the wider industry.

當然,審視這些預測的另一種方式就是將其與行業本身放在一個背景下進行考量。從最新的預估中可以明顯看出,Zymeworks的增長速度預計會加速,預計到2025年年底年化營收增長率將達到47%,明顯快於過去五年38%的歷史增長率。相比之下,我們的數據顯示,其他類似行業(有分析師覆蓋)的公司預計其營業收入每年增長21%。很顯然,雖然增長前景比最近的過去更爲光明,但分析師們也期待Zymeworks增長速度超過更廣泛行業的增長速度。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most important thing to take away is that analysts cut their revenue estimates for next year. They're also forecasting more rapid revenue growth than the wider market. There was also an increase in the price target, suggesting that there is more optimism baked into the forecasts than there was previously. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Zymeworks after today.

最重要的一點是,分析師們調低了明年的營業收入預期。他們還預測營業收入增速將比整個市場更快。價格目標也有所增加,表明預測中蘊含的樂觀情緒比之前更多。通常情況下,一次下調會引發連鎖反應,特別是當行業處於衰退時。因此,如果市場在今天之後變得更加謹慎,對Zymeworks感到意外也就不足爲奇。

Unanswered questions? At least one of Zymeworks' seven analysts has provided estimates out to 2026, which can be seen for free on our platform here.

有未解決的問題嗎?至少有一名Zymeworks的七名分析師提供了截至2026年的預測,可以在我們的平台上免費查看。

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

當然,看到公司管理層投入大量資金投資股票的情況與分析師是否對其評級下調一樣有用。因此,您還可以搜索此處的高內部所有權股票的免費列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論